<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Emerg Infect Dis</journal-id>
      <journal-id journal-id-type="iso-abbrev">Emerging Infect. Dis</journal-id>
      <journal-id journal-id-type="publisher-id">EID</journal-id>
      <journal-title-group>
        <journal-title>Emerging Infectious Diseases</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1080-6040</issn>
      <issn pub-type="epub">1080-6059</issn>
      <publisher>
        <publisher-name>Centers for Disease Control and Prevention</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">22607719</article-id>
      <article-id pub-id-type="pmc">3358177</article-id>
      <article-id pub-id-type="publisher-id">12-0302</article-id>
      <article-id pub-id-type="doi">10.3201/eid1806.120302</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letters to the Editor</subject>
        </subj-group>
        <subj-group subj-group-type="article-type">
          <subject>Letter</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Apparent Triclabendazole-Resistant Human <italic>Fasciola hepatica</italic> Infection, the Netherlands</article-title>
        <alt-title alt-title-type="running-head">Triclabendazole-Resistant <italic>F. hepatica</italic></alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Winkelhagen</surname>
            <given-names>Annemarie J.S.</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mank</surname>
            <given-names>Theo</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>de Vries</surname>
            <given-names>Peter J.</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Soetekouw</surname>
            <given-names>Robin</given-names>
          </name>
        </contrib>
        <aff id="aff1">Kennemer Gasthuis, Haarlem, the Netherlands (A.J.S. Winkelhagen, R. Soetekouw);</aff>
        <aff id="aff2">Streeklaboratorium voor de Volksgezondheid, Haarlem (T. Mank);</aff>
        <aff id="aff3">Academic Medical Center, Amsterdam, the Netherlands (P.J. de Vries)</aff>
      </contrib-group>
      <author-notes>
        <corresp id="cor1">Address for correspondence: Annemarie J.S. Winkelhagen, Boerhaavelaan 22, 2035 RC, Haarlem, the Netherlands; email: <email xlink:href="awinkelhagen@hotmail.com">awinkelhagen@hotmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>6</month>
        <year>2012</year>
      </pub-date>
      <volume>18</volume>
      <issue>6</issue>
      <fpage>1028</fpage>
      <lpage>1029</lpage>
      <kwd-group kwd-group-type="author">
        <title>Keywords: </title>
        <kwd>Fasciola hepatica</kwd>
        <kwd>fascioliasis</kwd>
        <kwd>triclabendazole</kwd>
        <kwd>drug resistance</kwd>
        <kwd>the Netherlands</kwd>
        <kwd>parasites</kwd>
        <kwd>trematode</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <p><bold>To the Editor:</bold> In December 2007, a 71-year-old sheep farmer sought care with a 4-month history of intermittent right upper quadrant pain, night sweats, anorexia, and a 5-kg weight loss. His medical history was unremarkable, and he had not traveled outside the Netherlands for &#x2248;30 years. Physical examination revealed no abnormalities.</p>
    <p>Blood tests showed an elevated erythrocyte sedimentation rate of 35 mm/h (reference 1&#x2013;15 mm/h), normocytic anemia (hemoglobin 7.0 mmol/L [reference 8.5&#x2013;11 mmol/L]), and eosinophilia (2.5 &#xD7; 10<sup>9</sup> cells/L [reference 0.0&#x2013;0.5 &#xD7; 10<sup>9</sup> cells/L]). Levels of alkaline phosphatase, &#x3B3;-glutamyl transferase, and alanine aminotransferase were elevated (146 U/L [reference 10&#x2013;120 U/L], 143 U/L [reference 5&#x2013;50 IU/L], and 54 U/L [reference 0&#x2013;45 U/L], respectively). Levels of bilirubin and aspartate aminotransferase were normal. Computed tomography of the liver showed several irregularly shaped low-attenuating lesions ranging in size from 1 to 4 cm. High titers of IgG (640 [cutoff 40], determined by enzyme immunoassay) against <italic>Fasciola hepatica</italic> were detected. Subsequently, <italic>F. hepatica</italic> eggs were detected in fecal samples.</p>
    <p>The patient, who spontaneously had become asymptomatic shortly after seeking care, was treated unsuccessfully with the benzimidazole derivative triclabendazole (TCBZ) on 3 separate occasions during the next 2 years. He was first treated with a single dose of 10 mg/kg TCBZ (Fasinex suspension; Novartis Animal Health Ltd., Surrey, UK), then with 2 doses 24 hours apart, and on the last occasion with 2 doses of TCBZ (Egaten; Sipharm Sisseln AG, Sisseln, Switzerland) 10 mg/kg 12 hours apart; the last 4 treatments were taken with food. Feces remained positive for <italic>F. hepatica</italic> eggs after each treatment. IgG titers remained positive (320, by enzyme immunoassay), and flukes could be visualized by ultrasound in the gallbladder and common bile duct (<xref ref-type="fig" rid="F1">Figure</xref>). Thereafter, the patient was treated with nitazoxanide (500 mg 2&#xD7;/d for 7 days); however, fecal samples remained positive for <italic>F. hepatica</italic> eggs. Lastly, after recent experiments of a combination therapy in a rat model (<xref ref-type="bibr" rid="R1"><italic>1</italic></xref>), we treated the patient with TCBZ (Egaten, 10 mg/kg) combined with ketoconazol 10 mg/kg taken with food. Still, his feces remained positive for <italic>F. hepatica</italic> eggs.</p>
    <fig id="F1" fig-type="figure" position="float">
      <label>Figure</label>
      <caption>
        <p>A) Ultrasound of the liver of a patient with <italic>Fasciola hepatica</italic> infection, the Netherlands. B) Drawing of A; depicted are the liver (white), the common bile duct (gray), and the portal vein (black). A fluke (white), measuring 2.5&#x2013;3 cm long, is identified in the common bile duct.</p>
      </caption>
      <graphic xlink:href="12-0302-F"/>
    </fig>
    <p>Fascioliasis is a zoonotic disease caused by the foodborne trematode <italic>F. hepatica</italic> or <italic>F. gigantica</italic>, which has a complex life cycle and mainly affects sheep and cattle (<xref ref-type="bibr" rid="R2"><italic>2</italic></xref>). Eggs of the adult worms (2&#x2013;4 cm) that live in the bile ducts of the final host are excreted in the feces and develop into larvae (miracidia) in water. The miracidia then penetrate, and further develop in, snails of the family Lymnaeidae. Free-swimming cercariae exit the snail and attach to aquatic vegetation, where they encyst as metacercariae. After ingestion by the host, they excyst in the intestine and migrate through the intestinal wall to the liver, where they mature into adult flatworms that reside in the bile ducts (<xref ref-type="bibr" rid="R2"><italic>2</italic></xref>).</p>
    <p>Fascioliasis affects millions of humans worldwide (<xref ref-type="bibr" rid="R3"><italic>3</italic></xref>); however, fascioliasis acquired in the Netherlands has been reported only sporadically (<xref ref-type="bibr" rid="R4"><italic>4</italic></xref>), even though <italic>F. hepatica</italic> infection in sheep and cattle is prevalent there (<xref ref-type="bibr" rid="R5"><italic>5</italic></xref>). The patient in this report had not eaten watercress or other aquatic plants and had not ingested ditchwater. However, he had worked in and around ditches on farms in the area, admitted chewing grass sporadically, and might have occasionally ingested vegetables previously fertilized with livestock manure. The patient remains asymptomatic but infected.</p>
    <p>TCBZ is the treatment of choice for fascioliasis. In a review by Keiser et al. (<xref ref-type="bibr" rid="R6"><italic>6</italic></xref>), the efficacy of treatment with TCBZ was shown to yield egg clearance in 78%&#x2013;100% of patients after 1 dose of 10 mg/kg and in 92%&#x2013;100% after 2 doses of 10 mg/kg each 12 or 24 hours apart. In livestock, TCBZ resistance is being reported increasingly (<xref ref-type="bibr" rid="R7"><italic>7</italic></xref>). Mass treatment of sheep and cattle with TCBZ (Fasinex) or in combination with other anthelmintic drugs is common in the Netherlands (L. Moll, pers. comm.), and the first cases of resistance were described in 1998 in sheep and cattle in the province of North Holland, the area of residence of the patient reported in this study (<xref ref-type="bibr" rid="R8"><italic>8</italic></xref><italic>,</italic><xref ref-type="bibr" rid="R9"><italic>9</italic></xref>). During 1998&#x2013;2004, resistance to TCBZ, proven by fecal egg count reduction tests, was found on 14 farms in the same area (<xref ref-type="bibr" rid="R5"><italic>5</italic></xref>).</p>
    <p>The findings in this case are most likely explained by TCBZ resistance, although we note that repeated TCBZ courses are not 100% effective against fascioliasis (<xref ref-type="bibr" rid="R6"><italic>6</italic></xref>). Re-infection can be excluded because fecal samples were tested for eggs 1&#x2013;3 months after each treatment. This description of apparent TCBZ-resistant fascioliasis in a human highlights the human health implications of (massive) anthelmintic use in livestock.</p>
    <p>Further studies on TCBZ resistance and on therapeutics for fascioliasis need to be conducted. In addition, the role of antimicrobial drugs in the treatment of livestock needs to be more rigorously evaluated.</p>
  </body>
  <back>
    <fn-group>
      <fn fn-type="citation">
        <p><italic>Suggested citation of this article:</italic> Winkelhagen AJS, Mank T, de Vries PJ, Soetekouw R. Triclabendazole-resistant human <italic>Fasciola hepatica</italic> infection, the Netherlands [letter]. Emerg Infect Dis [serial on the Internet] 2012 Jun [<italic>date cited</italic>]. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3201/eid1806.111038">http://dx.doi.org/10.3201/eid1806.111038</ext-link></p>
      </fn>
    </fn-group>
    <ack>
      <title>Acknowledgments</title>
      <p>We thank R.H. Kruyt for providing the ultrasound image and the department of parasitology, Leiden University Medical Center, for conducting the serologic tests.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="R1">
        <label>1. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Devine</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Brennan</surname>
<given-names>GP</given-names></string-name>, <string-name><surname>Lanusse</surname>
<given-names>CE</given-names></string-name>, <string-name><surname>Alvarez</surname>
<given-names>LI</given-names></string-name>, <string-name><surname>Trudgett</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Hoey</surname>
<given-names>E</given-names></string-name>, <etal/>
<article-title>Potentiation of triclabendazole action in vivo against a triclabendazole-resistant isolate of <italic>Fasciola hepatica</italic> following its co-administration with the metabolic inhibitor, ketoconazole.</article-title>
<source>Vet Parasitol</source>. <year>2012</year>;<volume>184</volume>:<fpage>37</fpage>&#x2013;<lpage>47</lpage>
<pub-id pub-id-type="doi">10.1016/j.vetpar.2011.08.006</pub-id><pub-id pub-id-type="pmid">21872399</pub-id></mixed-citation>
      </ref>
      <ref id="R2">
        <label>2. </label>
        <mixed-citation publication-type="book"><string-name><surname>Eberhard</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Engels</surname>
<given-names>D</given-names></string-name> Fascioliasis. In: Heymann DL, editor. Control of communicable diseases manual, 19th ed. Washington (DC): American Public Health Association; <year>2008</year> p. 230&#x2013;1.</mixed-citation>
      </ref>
      <ref id="R3">
        <label>3. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Mas-Coma</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Valero</surname>
<given-names>MA</given-names></string-name>, <string-name><surname>Bargues</surname>
<given-names>MD</given-names></string-name>
<article-title><italic>Fasciola</italic>, lymnaeids and human fascioliasis, with a global overview on disease transmission, epidemiology, evolutionary genetics, molecular epidemiology and control.</article-title>
<source>Adv Parasitol</source>. <year>2009</year>;<volume>69</volume>:<fpage>41</fpage>&#x2013;<lpage>146</lpage>
<pub-id pub-id-type="doi">10.1016/S0065-308X(09)69002-3</pub-id><pub-id pub-id-type="pmid">19622408</pub-id></mixed-citation>
      </ref>
      <ref id="R4">
        <label>4. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Wagener</surname>
<given-names>DJT</given-names></string-name>, <string-name><surname>van Tongeren</surname>
<given-names>JHM</given-names></string-name>, <string-name><surname>Meuwissen</surname>
<given-names>JHET</given-names></string-name>
<article-title><italic>Fasciola hepatica</italic> infection; an unusual cause of severe anemia</article-title>
<comment>[in Dutch]</comment>
<source>Ned Tijdschr Geneeskd</source>. <year>1972</year>;<volume>116</volume>:<fpage>431</fpage>&#x2013;<lpage>5</lpage><pub-id pub-id-type="pmid">5010739</pub-id></mixed-citation>
      </ref>
      <ref id="R5">
        <label>5. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Borgsteede</surname>
<given-names>FHM</given-names></string-name>, <string-name><surname>Moll</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Vellema</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Gaasenbeek</surname>
<given-names>CPH</given-names></string-name>
<article-title>Lack of reversion in triclabendazole-resistant <italic>Fasciola hepatica.</italic></article-title>
<source>Vet Rec</source>. <year>2005</year>;<volume>156</volume>:<fpage>350</fpage>&#x2013;<lpage>1</lpage><pub-id pub-id-type="pmid">15789649</pub-id></mixed-citation>
      </ref>
      <ref id="R6">
        <label>6. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Keiser</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Engels</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Buscher</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Utzinger</surname>
<given-names>J</given-names></string-name>
<article-title>Triclabendazole for the treatment of fascioliasis and paragonimiasis.</article-title>
<source>Expert Opin Investig Drugs</source>. <year>2005</year>;<volume>14</volume>:<fpage>1513</fpage>&#x2013;<lpage>26</lpage>
<pub-id pub-id-type="doi">10.1517/13543784.14.12.1513</pub-id><pub-id pub-id-type="pmid">16307491</pub-id></mixed-citation>
      </ref>
      <ref id="R7">
        <label>7. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Fairweather</surname>
<given-names>I</given-names></string-name>
<article-title>Reducing the future threat from (liver) fluke: realistic prospect or quixotic fantasy?</article-title>
<source>Vet Parasitol</source>. <year>2011</year>;<volume>180</volume>:<fpage>133</fpage>&#x2013;<lpage>43</lpage>
<pub-id pub-id-type="doi">10.1016/j.vetpar.2011.05.034</pub-id><pub-id pub-id-type="pmid">21703766</pub-id></mixed-citation>
      </ref>
      <ref id="R8">
        <label>8. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Moll</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Gaasenbeek</surname>
<given-names>CPH</given-names></string-name>, <string-name><surname>Vellema</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Borgsteede</surname>
<given-names>FHM</given-names></string-name>
<article-title>Resistance of <italic>Fasciola hepatica</italic> against triclabendazole in cattle and sheep in the Netherlands.</article-title>
<source>Vet Parasitol</source>. <year>2000</year>;<volume>91</volume>:<fpage>153</fpage>&#x2013;<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1016/S0304-4017(00)00267-3</pub-id><pub-id pub-id-type="pmid">10889368</pub-id></mixed-citation>
      </ref>
      <ref id="R9">
        <label>9. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Gaasenbeek</surname>
<given-names>CPH</given-names></string-name>, <string-name><surname>Moll</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Cornelissen</surname>
<given-names>JBWJ</given-names></string-name>, <string-name><surname>Vellema</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Borgsteede</surname>
<given-names>FHM</given-names></string-name>
<article-title>An experimental study on triclabendazole resistance of <italic>Fasciola hepatica</italic> in sheep.</article-title>
<source>Vet Parasitol</source>. <year>2001</year>;<volume>95</volume>:<fpage>37</fpage>&#x2013;<lpage>43</lpage>
<pub-id pub-id-type="doi">10.1016/S0304-4017(00)00413-1</pub-id><pub-id pub-id-type="pmid">11163696</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
